JP2017515792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515792A5 JP2017515792A5 JP2016555508A JP2016555508A JP2017515792A5 JP 2017515792 A5 JP2017515792 A5 JP 2017515792A5 JP 2016555508 A JP2016555508 A JP 2016555508A JP 2016555508 A JP2016555508 A JP 2016555508A JP 2017515792 A5 JP2017515792 A5 JP 2017515792A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 25
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 3
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 102000046828 human IL1RAP Human genes 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1403875.6 | 2014-03-05 | ||
| GBGB1403875.6A GB201403875D0 (en) | 2014-03-05 | 2014-03-05 | Novel antibodies and uses thereof |
| PCT/GB2015/050647 WO2015132602A1 (en) | 2014-03-05 | 2015-03-05 | Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515792A JP2017515792A (ja) | 2017-06-15 |
| JP2017515792A5 true JP2017515792A5 (show.php) | 2018-04-12 |
| JP6396488B2 JP6396488B2 (ja) | 2018-09-26 |
Family
ID=50490826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555508A Active JP6396488B2 (ja) | 2014-03-05 | 2015-03-05 | 抗ヒトインターロイキン−１受容体アクセサリータンパク質（ｉｌ１ ｒａｐ）抗体およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9796783B2 (show.php) |
| EP (2) | EP3114145B1 (show.php) |
| JP (1) | JP6396488B2 (show.php) |
| KR (1) | KR102519196B1 (show.php) |
| CN (1) | CN106459195B (show.php) |
| AU (1) | AU2015225948B2 (show.php) |
| CA (1) | CA2941437C (show.php) |
| DK (2) | DK3293202T3 (show.php) |
| ES (2) | ES2861582T5 (show.php) |
| GB (1) | GB201403875D0 (show.php) |
| IL (1) | IL247459B (show.php) |
| LT (1) | LT3114145T (show.php) |
| MX (1) | MX360497B (show.php) |
| PL (1) | PL3114145T3 (show.php) |
| PT (1) | PT3114145T (show.php) |
| RU (1) | RU2710787C2 (show.php) |
| SG (1) | SG11201607322PA (show.php) |
| WO (1) | WO2015132602A1 (show.php) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CN107929730A (zh) | 2011-01-19 | 2018-04-20 | 坎塔吉亚有限责任公司 | 抗il1rap抗体及其治疗人类的用途 |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| ES2876430T3 (es) | 2014-02-10 | 2021-11-12 | Merck Patent Gmbh | Inhibición dirigida de TGFß |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
| TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
| CA2990305A1 (en) | 2015-06-26 | 2016-12-29 | Mab Discovery Gmbh | Monoclonal anti-il-1racp antibodies |
| EP3356393A4 (en) * | 2015-10-01 | 2019-08-07 | Heat Biologics, Inc. | COMPOSITIONS AND METHODS OF ADJUSTING TYPE I AND TYPE II EXTRACELLULAR DOMAINS AS HETEROLOGICAL CHIMERIC PROTEINS |
| CN108603877A (zh) * | 2015-10-02 | 2018-09-28 | Tgr生物科学私人有限公司 | 使用多基质的分析物检测 |
| CR20180250A (es) * | 2015-11-02 | 2018-10-01 | Janssen Pharmaceutica Nv | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y uso de estas |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| JP7032394B2 (ja) * | 2016-10-16 | 2022-03-30 | カンタージア アクチエボラーグ | 抗ｉｌ１－ｒａｐ抗体 |
| WO2018102682A1 (en) | 2016-12-01 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| KR102813603B1 (ko) | 2017-02-10 | 2025-05-29 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체 |
| EP3589295B1 (en) | 2017-02-28 | 2024-09-11 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US20180280437A1 (en) * | 2017-03-13 | 2018-10-04 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
| US11433148B2 (en) | 2017-05-05 | 2022-09-06 | Centre For Probe Development And Commercialization | IGF-1R monoclonal antibodies and uses thereof |
| US10093741B1 (en) * | 2017-05-05 | 2018-10-09 | Fusion Pharmaceuticals Inc. | IGF-1R monoclonal antibodies and uses thereof |
| CA3062553C (en) | 2017-05-05 | 2024-02-06 | Fusion Pharmaceuticals Inc. | Pharmacokinetic enhancements of bifunctional chelates and uses thereof |
| EP3401332A1 (en) * | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| IL316355A (en) | 2017-07-24 | 2024-12-01 | Regeneron Pharma | Anti-CD8 antibodies and their uses |
| AU2018312563A1 (en) * | 2017-08-01 | 2020-03-12 | City Of Hope | Anti-IL1RAP antibodies |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| CA3089319A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CN110759989B (zh) * | 2018-07-27 | 2021-08-17 | 中国人民解放军总医院 | IL-36γ作为动脉粥样硬化的标志物 |
| EP3837283B1 (en) * | 2018-08-16 | 2024-04-17 | Cantargia AB | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| MA54401A (fr) * | 2018-12-03 | 2021-10-13 | Fusion Pharmaceuticals Inc | Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn |
| US11884719B2 (en) | 2018-12-21 | 2024-01-30 | 23Andme, Inc. | Anti-IL-36 antibodies and methods of use thereof |
| CN113710229B (zh) | 2019-02-25 | 2026-01-06 | 芝加哥大学 | 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物 |
| CN110564848A (zh) * | 2019-04-15 | 2019-12-13 | 上海市同仁医院 | 白介素-36在制备结直肠癌预后产品中的应用 |
| WO2020215051A1 (en) * | 2019-04-19 | 2020-10-22 | Rpi Consulting Llc | Treatments for pregnancy-related conditions |
| WO2020261097A1 (en) * | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| WO2021030484A2 (en) * | 2019-08-12 | 2021-02-18 | City Of Hope | Il1rap antibodies |
| CR20220461A (es) | 2020-03-13 | 2022-10-21 | Genentech Inc | Anticuerpos anti-interleucina-33 y usos de estos |
| JP2023521174A (ja) * | 2020-04-10 | 2023-05-23 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体 |
| JP2023525826A (ja) * | 2020-05-12 | 2023-06-19 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｓｔ２抗原結合タンパク質 |
| PE20231575A1 (es) | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | Anticuerpos que se unen a il1rap y usos de estos |
| CA3202942A1 (en) | 2020-12-23 | 2022-06-30 | David LIBERG | Anti-il1rap antibody |
| CA3220913A1 (en) | 2021-05-21 | 2022-11-24 | Leo Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| WO2024011189A2 (en) * | 2022-07-06 | 2024-01-11 | Bluefin Biomedicine, Inc. | Methods of treating disease using anti-il1rap antibodies and antibody drug conjugates |
| KR20250060305A (ko) | 2022-09-21 | 2025-05-07 | 사노피 바이오테크놀로지 | 인간화 항-il-1r3 항체 및 사용 방법 |
| CN121263442A (zh) * | 2023-05-05 | 2026-01-02 | 大塚制药株式会社 | 抗il1rap抗体 |
| WO2025126157A1 (en) * | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| CN118772268B (zh) * | 2024-09-10 | 2025-02-11 | 山东第二医科大学 | 猴痘病毒a29l单克隆抗体、试剂盒及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| PE64396A1 (es) † | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US20030215453A1 (en) | 2002-05-14 | 2003-11-20 | Dedera Douglas A. | Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR20060031809A (ko) | 2003-06-09 | 2006-04-13 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 암 치료 및 진단용 조성물 및 방법 |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| WO2006020114A2 (en) | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
| WO2008049098A2 (en) * | 2006-10-19 | 2008-04-24 | Merck & Co., Inc. | ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1 |
| US7776331B1 (en) * | 2007-01-16 | 2010-08-17 | Abbott Laboratories | Methods of treating plaque psoriasis |
| EP4470556A3 (en) | 2008-01-15 | 2025-04-23 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2009120905A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| CN107929730A (zh) * | 2011-01-19 | 2018-04-20 | 坎塔吉亚有限责任公司 | 抗il1rap抗体及其治疗人类的用途 |
| EP2723365A1 (en) * | 2011-06-21 | 2014-04-30 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| CN103077969B (zh) | 2011-10-26 | 2016-03-30 | 中国科学院微电子研究所 | 一种mos器件及其制造方法 |
| WO2014113433A1 (en) | 2013-01-16 | 2014-07-24 | George Mason University | Binding domain mapping |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| CA2990305A1 (en) | 2015-06-26 | 2016-12-29 | Mab Discovery Gmbh | Monoclonal anti-il-1racp antibodies |
| CR20180250A (es) | 2015-11-02 | 2018-10-01 | Janssen Pharmaceutica Nv | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y uso de estas |
| WO2018071910A2 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| JP7032394B2 (ja) | 2016-10-16 | 2022-03-30 | カンタージア アクチエボラーグ | 抗ｉｌ１－ｒａｐ抗体 |
-
2014
- 2014-03-05 GB GBGB1403875.6A patent/GB201403875D0/en not_active Ceased
-
2015
- 2015-03-05 KR KR1020167027523A patent/KR102519196B1/ko active Active
- 2015-03-05 EP EP15714603.6A patent/EP3114145B1/en active Active
- 2015-03-05 MX MX2016011414A patent/MX360497B/es active IP Right Grant
- 2015-03-05 LT LTEP15714603.6T patent/LT3114145T/lt unknown
- 2015-03-05 SG SG11201607322PA patent/SG11201607322PA/en unknown
- 2015-03-05 AU AU2015225948A patent/AU2015225948B2/en active Active
- 2015-03-05 PT PT157146036T patent/PT3114145T/pt unknown
- 2015-03-05 CA CA2941437A patent/CA2941437C/en active Active
- 2015-03-05 JP JP2016555508A patent/JP6396488B2/ja active Active
- 2015-03-05 CN CN201580019206.1A patent/CN106459195B/zh active Active
- 2015-03-05 DK DK17185792.3T patent/DK3293202T3/da active
- 2015-03-05 DK DK15714603.6T patent/DK3114145T3/da active
- 2015-03-05 EP EP17185792.3A patent/EP3293202B2/en active Active
- 2015-03-05 ES ES17185792T patent/ES2861582T5/es active Active
- 2015-03-05 RU RU2016139068A patent/RU2710787C2/ru active
- 2015-03-05 ES ES15714603.6T patent/ES2646550T3/es active Active
- 2015-03-05 WO PCT/GB2015/050647 patent/WO2015132602A1/en not_active Ceased
- 2015-03-05 PL PL15714603T patent/PL3114145T3/pl unknown
-
2016
- 2016-08-24 IL IL24745916A patent/IL247459B/en active IP Right Grant
- 2016-09-02 US US15/255,585 patent/US9796783B2/en active Active
-
2017
- 2017-09-18 US US15/707,593 patent/US10287357B2/en active Active
-
2019
- 2019-03-19 US US16/358,459 patent/US10752692B2/en active Active
-
2020
- 2020-07-16 US US16/930,631 patent/US11236172B2/en active Active
-
2021
- 2021-12-15 US US17/551,908 patent/US12398213B2/en active Active
-
2025
- 2025-07-14 US US19/267,857 patent/US20250340657A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515792A5 (show.php) | ||
| JP7118117B2 (ja) | 抗体－薬物コンジュゲートの選択的製造方法 | |
| JP7150820B2 (ja) | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート | |
| JP2017186337A5 (show.php) | ||
| JP2022084608A (ja) | 抗ｔｒｏｐ２抗体－薬物コンジュゲート | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| JP2020536109A5 (show.php) | ||
| JP2017535257A5 (show.php) | ||
| JP2009505676A5 (show.php) | ||
| JP2019107018A5 (show.php) | ||
| JP2017537620A5 (show.php) | ||
| JP2012529281A5 (show.php) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2015534577A5 (show.php) | ||
| RU2012137502A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2016505513A5 (show.php) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| RU2012137504A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| TW201620553A (zh) | 抗ｃｄ９８抗體－藥物結合物 | |
| JP2010110329A5 (show.php) | ||
| JP2010531140A5 (show.php) | ||
| JP2017530692A5 (show.php) | ||
| JP2020502271A5 (show.php) | ||
| JP2017507936A5 (show.php) | ||
| JP2009526010A5 (show.php) |